14669 results for "PLOS+ONE+Pennsylvania+German+ACS+language+code+pdc+open+access+study"

in 27.38 milliseconds.

• Noninvasive prenatal molecular karyotyping from maternal plasma

  Study EGAS00001000439

• Cetuximab treatment of metastasis-derived organoids (LMO)

  Study EGAS00001006601

• Placental microRNA sequencing data from human placenta

  Study EGAS00001005378

• GWAS Steroid Sensitive Nephrotic Syndrome

  Study EGAS00001003607

• Hi-C on the OCIAML-2 Cell Line

  Study EGAS00001004743

• Circadian Clock Properties of T2D Patients

  Study EGAS00001003622

• APL Oxford Nanopore sequencing - nanome

  Study EGAS00001005613

• Comparative analysis of RAF depletion vs. MAPK inhibition

  Study EGAS00001005743

• Paired healthy & tumor organoid Biobank _B15PON

  Study EGAS00001005865

• RNA-seq data from 27 glioblastoma samples

  Study EGAS00001005807

• TLR7 variants in human lupus patients

  Study EGAS00001005965

• RNAseq analysis on metastasis-derived organoids (LMO)

  Study EGAS00001007024

• Non-small cell lung cancer sequencing

  Study EGAS00001005499

• Multi-region sequencing of PDAC patients

  Study EGAS00001007379

• Platelet DNA study Murphy et al 2023 DAC

  Dac EGAC00001003034

• Single-cell analysis of retinoblastoma heterogeneity

  Study EGAS00001005178

• Single-Cell NSC DAC – ADHD and Control iPSC Study

  Dac EGAC00001003572

• ATACseq in blood-derived monocytes from CGD patients

  Study EGAS00001005915

• Berlin Neuroblastoma Dataset

  Study EGAS00001004022

• Leeds_Melanoma_Cohort

  Leeds Melanoma Cohort

  Study EGAS00001001158

• Comparison of the performance of two commercial genome-wide association study genotyping platforms in Han Chinese Samples

  Affymetrix 6.0, Illumina OMNIExpress, and llumina Immunochip genotype data for Han Chinese population including rheumatoid arthritis cases and controls. Data is in PLINK binary format. Illumina genotype clustering was performed using Illumina’s BeadStudio software. SNPs were reclustered using the study samples, low quality subjects were removed, and a subset of clustering results were manually inspected and verified. All SNPs with GenCall scores less than 0.15 were excluded. For Affymetrix chips, clustering was performed using the program Birdseed version 2, as implemented using Affymetrix Genotyper Console v4.0, using the default quality control (QC) thresholds.

  Study EGAS00000000131

• Genetics of Pigmentation in Eastern and Southern African Populations Study

  The goal of this study was to identify genes and loci associated with pigmentation in African populations. It comprises 1,593 participants from Ethiopia, Tanzania, and Botswana. Sexes are evenly represented (768 males and 825 females) and self reported ages ranged from 18 to 103. Mean age was used for individuals without ages. For each participant, a DSM II color meter was used to measure underarm skin reflectance in triplicate. These measures averaged and converted to a melanin index (MI = 100 x log10(1/(x/255)). All individuals were included in a genome wide scan that accounted for age, sex, and genetic relatedness.

  Study phs001396

• A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

  Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is characterized by poor outcomes and novel therapeutic options are urgently needed. Immune checkpoint blockade using CTLA-4 and PD-1 blocking antibodies are a potential concept for reinstating a dormant graft-versus-leukemia (GvL) effect.This study investigated transcriptomic changes in biopsies obtained from patients who received immune checkpoint blockade for relapsed hematologic malignancy post-HSCT and elucidated transcriptional programs associated with successful reinvigoration of GvL. Differential gene expression analysis showed evidence of increased T cell infiltration in biopsies of responders to ipilimumab treatment and demonstrated shared gene programs between GvL and GvHD.

  Study phs002377

• My Pediatric and Adult Rare Tumor (MyPART) Natural History Study of Rare Solid Tumors

  The goal of this study is to comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival). Clinical data, patient reported outcomes (PROs), and biospecimen associated data are collected. Clinical data includes response to treatment, tumor pathology, and imaging. PROs include measures of pain, depression, anxiety, mobility, and cognitive functioning. Biospecimen data includes next-generation sequencing [RNAseq, whole exome sequencing (WES), whole genome sequencing (WGS), EPIC methylation array data, and TruSight Oncology 500 gene panel sequencing], cytokine analysis of plasma, immune phenotyping of circulating peripheral blood mononuclear cells.

  Study phs003143

• Whole-genome variant calling of individuals from the study of allergic diseases in the Canary Islands

  Research study of genetic susceptibility and analyses of polygenic risk scores in allergic diseases. The historic influences in the Canary Islanders have resulted in an admixture of European, North Africans and Sub-saharan African genetic ancestries. Genetic risks linked to any of these ancestries could underlie disease peculiarities in the current inhabitants. To leverage genectic ancestry to identify and assess genetic risks in allergic diseases in the Canary Islands, we combine different genomic technologies in case-control studies and reference samples from the three parental populations to characterize and identify genetic risks factors and the intersection with ancestry.

  Study EGAS50000000299